Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Jubilant Pharmova Limited ( (IN:JUBLPHARMA) ) is now available.
Jubilant Pharmova Limited announced that its subsidiary, Jubilant Biosys Innovative Research Services Pte Limited (JBIRSPL), has acquired an 80% equity stake in JASMIN, a French company newly incorporated by Pierre Fabre SA, with the remaining 20% retained by Pierre Fabre. The transaction involves JASMIN acquiring Pierre Fabre’s R&D Centre in Saint Julien, France, and comes with a Shareholders’ Agreement and other transition agreements. This strategic acquisition marks an expansion of Jubilant Pharmova’s research and development capabilities in Europe and strengthens its position in the pharmaceutical industry.
More about Jubilant Pharmova Limited
Jubilant Pharmova Limited operates in the pharmaceutical industry, focusing on research and development services. It primarily provides innovative research services through its subsidiary Jubilant Biosys Limited.
YTD Price Performance: -16.71%
Average Trading Volume: 25,336
Current Market Cap: 147B INR
For detailed information about JUBLPHARMA stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue